Showing results (2211-2220 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|February 27, 2018
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Robert F Wolff, Xavier Pouwels, et al.
Pharmacoeconomics|June 27, 2022
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in AustraliaRachel Song, Varinder Jeet, Rajan Sharma, et al.
Pharmacoeconomics|June 14, 2022
Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling StudyShuxia Qin, Xuehong Wang, Sini Li, et al.
Pharmacoeconomics|July 2, 2022
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the USHardik Goswami, Adnan Alsumali, Yiling Jiang, et al.
Pharmacoeconomics|June 28, 2022
The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial ResistanceSimon van der Pol, Danielle E M C Jansen, Alike W van der Velden, et al.
Pharmacoeconomics|June 28, 2022
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in ChinaYichen Zhang, Yuxuan Wei, Huangqianyu Li, et al.
Pharmacoeconomics|June 5, 2021
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal CancerYat Hang To, Koen Degeling, Suzanne Kosmider, et al.
Pharmacoeconomics|February 14, 2020
Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic DrugsSalah Ghabri, Laurent Lam, François Bocquet, et al.
Pharmacoeconomics|February 26, 2020
Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP DisparityAdriënne H Rotteveel, Mattijs S Lambooij, Nicolaas P A Zuithoff, et al.
Pharmacoeconomics|January 25, 2020
Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best-Worst ScalingKim Dalziel, Max Catchpool, Borja García-Lorenzo, et al.
Pageof 336